QuantiLight

What QuantiLight does

QuantiLight is a Heidelberg, Germany-based diagnostic technology company developing an at-home therapeutic drug monitoring (TDM) platform. The company originated as a 2022 research project at the Department of Chemical Biology at the Max Planck Institute for Medical Research and was formally incorporated as QuantiLight GmbH in Q2 2025. It is led by two PhD founders — Dr. Corentin Gondrand (CEO, PhD Chemical Biology) and Dr. Estelle Bonedeau (CTO, PhD Molecular Biology) — and is supported by an advisory board drawn from the Max Planck Institute, University Clinic Heidelberg, Harvard Medical School, and commercial biotech/medtech executives. The company targets chronic patients, initially organ transplant recipients requiring immunosuppressant monitoring and patients with chronic kidney or liver disease, addressing a globally cited population of approximately 23 million TDM patients.

The core technology is a patented bioluminescent sensor platform built on peer-reviewed research published in Nature Chemical Biology, Science, and Nature Metabolism. The semisynthetic sensor proteins emit light whose color (red to blue) shifts based on receptor occupancy by target analytes, enabling quantification of drugs and biomarkers at nanomolar concentrations in complex biological matrices. The system is delivered through four integrated components: a single-use test cartridge that processes 5μl of finger-prick blood, a hand-held portable reader device (shoebox-sized), and a Bluetooth-connected mobile application for result display and clinician communication. Quantitative results are delivered in 15 minutes, compared to days for standard laboratory testing.

QuantiLight plans a B2B2C distribution model — cartridges as recurring consumables, the reader as one-time hardware, and a subscription-based mobile application — with cartridges sold via prescription or healthcare-provider referral to patients for at-home self-testing. The company is pre-commercial and currently raising a seed round (amount undisclosed) to finalize the commercial platform, advance clinical trials, and scale the team. To date, the only external capital has been a non-dilutive EXIST-Forschungstransfer grant from the German Federal Ministry for Economic Affairs and Climate Action secured in Q1 2023. Market reach is currently limited to the DACH region, with global expansion implicit in the company's market sizing but not yet operationalized.

Name

QuantiLight

Legal name

QuantiLight GmbH

Website

https://quantilight.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

QuantiLight is a Heidelberg-based diagnostic company developing an at-home bioluminescent sensor platform for therapeutic drug monitoring, initially targeting organ transplant recipients and kidney/liver disease patients with a 15-minute finger-prick blood test system.

Ownership category

akta.pro rank

Product category

At-Home Therapeutic Drug Monitoring

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

akta.pro secondary industries

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL), Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers) (HLACAPAH)

Keywords

• Therapeutic drug monitoring
• Bioluminescent biosensors
• At-home diagnostics
• Point-of-care testing
• Transplant care devices

Headquarters

HQ city

Heidelberg

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Diagnostic Test Kits (Cartridges): Sale of disposable single-use test cartridges for at-home therapeutic drug monitoring. Patients purchase cartridges for regular monitoring of drug levels.
2. Portable Reader Device: Sale of handheld reading devices that interface with test cartridges. One-time hardware purchase.
3. Subscription/Mobile App Services: Mobile application providing data tracking, historical analysis, and healthcare provider communication. Likely subscription-based for ongoing monitoring services.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

QuantiLight develops and will sell an at-home therapeutic drug monitoring system that uses patented bioluminescent sensor technology to deliver quantitative drug-level results from a 5 microliter finger-prick blood sample in 15 minutes. The system combines a single-use test cartridge, a portable handheld Bluetooth reader, and a mobile app for data tracking and physician communication. Its first commercial focus is immunosuppressant drug monitoring for organ transplant recipients and kidney/liver function biomarker monitoring.

Product overview

QuantiLight offers a unified at-home therapeutic drug monitoring system consisting of four integrated components: the Bioluminescent Sensor Platform (core patented technology), the Test Cartridge (single-use consumable), the Reader (hand-held hardware device), and the Mobile App (patient-facing software). The system delivers quantitative drug concentration results from a fingerprick blood sample in 15 minutes, combining the Bioluminescent Sensor Platform with the proprietary cartridge-reader apparatus and Bluetooth-connected mobile application for real-time patient monitoring.

Differentiator

Problem solved

Functional benefit

Products and services

• At-Home Therapeutic Drug Monitoring System (Test Cartridge + Reader + Mobile App) Integrated at-home therapeutic drug monitoring system for chronic patients. A single-use test cartridge receives 5 microliters of finger-prick blood, dilutes it, and is analyzed by a handheld Bluetooth reader using QuantiLight's patented bioluminescent sensor platform. Results are delivered in 15 minutes via the mobile application, enabling quantitative drug and biomarker monitoring for organ transplant recipients and chronic kidney/liver disease patients in place of clinic-based lab testing.
• Test Cartridge Single-use consumable cartridge designed to receive a 5 microliter finger-prick blood sample, dilute the blood, and present it for analysis. Sold as a recurring consumable to enable repeat at-home drug and biomarker testing.
• Portable Reader Device Hand-held, shoebox-sized external reader that analyzes the inserted test cartridge using QuantiLight's proprietary patented sensor technology and transmits results to the mobile application via Bluetooth. Sold as a one-time hardware purchase paired with recurring cartridge sales.
• QuantiLight Mobile Application Mobile application that receives reader results over Bluetooth, displays current drug concentration to the patient, maintains historical tracking, and facilitates communication with physicians for treatment adjustments. Offered as part of the recurring monitoring experience.

Quantifiable outcome

• 23 million patients globally with the need for therapeutic drug monitoring
• +5 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Heidelberg University HospitalcoreStrategic or Co-development Partner · 1 January 2025Clinical collaboration with transplant nephrology department. Advisory support from Prof. Dr. Burkhard Tönshoff, Deputy Medical Director & Senior Physician at the Clinic for Nephropediatrics at University Clinic Heidelberg.
• Max Planck Institute for Medical ResearchcoreStrategic or Co-development Partner · 1 January 2022QuantiLight originated as a research project in 2022 in the Department of Chemical Biology at the Max Planck Institute for Medical Research in Heidelberg. The company's technology is rooted in academic research from this institution. Company co-located at the institute.
• Start2 AcceleratorminorGTM or Marketing PartnerAccelerator program accepted into for mentorship, networking, and business development support.
• Life Science Accelerator Baden-WürttembergminorGTM or Marketing PartnerRegional life science accelerator program providing mentorship and resources for commercialization.
• 4C Accelerator - Medical Innovations IncubatorminorGTM or Marketing PartnerMedical innovations incubator accelerator program for networking and business development.
• MAX!mize AcceleratorminorGTM or Marketing PartnerAccelerator program providing mentorship and business development support.
• Prof. Kai JohnssoncoreOthersDepartment Head of Chemical Biology at MPI for Medical Research. Scientific advisory board member and key technology contributor based on published research.
• Prof. Dr. med Burkhard TönshoffcoreOthersTransplant nephrologist at University Clinic Heidelberg, Deputy Medical Director & Senior Physician at Clinic for Nephropediatrics. Medical advisory board member providing clinical expertise.
• Dr. Saif A. Alenizi, MD, MPHminorOthersNephrologist at Brigham and Women's Hospital, Lecturer at Harvard Medical School, Associate Medical Director at Biogen. Medical advisory board member.
• Erin FedermanminorOthersCommercial advisory board member. Led global commercial strategy for 20+ biotech and medtech launches.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Roche Diagnostics: Roche operates the cobas central-lab and POC diagnostic franchise that includes therapeutic drug monitoring assays for immunosuppressants — the incumbent workflow QuantiLight aims to decentralize.
• Abbott: Abbott's i-STAT and ARCHITECT franchises provide point-of-care and central-lab diagnostics that include TDM assays. Broad incumbent with the distribution and regulatory infrastructure QuantiLight will need to compete against.
• Siemens Healthineers: Siemens Healthineers' epoc and ADVIA Centaur platforms deliver POC and central-lab diagnostics including TDM. Comparable as an established incumbent whose installed base QuantiLight must convince customers to complement or replace.

Emerging players

• Babson Diagnostics: Babson offers retail/home blood testing with a finger-prick sample and automated sample handling, sharing QuantiLight's decentralized, small-blood-volume diagnostic approach — though Babson targets broad chemistry panels rather than TDM.
• Tasso: Tasso produces at-home blood collection devices that enable remote sample-based diagnostics, overlapping with QuantiLight's home sample-collection workflow. Comparable as an enabling home blood-sampling player rather than a direct TDM competitor.

Direct peers

• Everlywell: Everlywell sells DTC at-home diagnostic test kits with a connected digital experience, sharing QuantiLight's direct-to-consumer home testing motion. It is a comparable channel/brand model rather than a chemistry-level competitor.
• Saladax Biomedical: Saladax develops blood-based tests for therapeutic drug monitoring (e.g., immunosuppressants, antipsychotics), directly overlapping with QuantiLight's TDM focus. Most comparable as a chemistry-driven TDM diagnostic peer; its technology was acquired by Myriad Genetics.
• Cue Health: Cue built a consumer/home molecular diagnostic platform with a proprietary reader, single-use test cartridges, and a connected mobile app — the same cartridge + reader + app architecture QuantiLight is developing, though Cue focused on respiratory/molecular targets rather than TDM.
• Healthy.io: Healthy.io delivers smartphone-based at-home diagnostic tests (notably for kidney disease/ACR), directly overlapping with QuantiLight's at-home kidney-function monitoring use case and direct-to-consumer go-to-market motion.

Regional players

• ARKRAY: ARKRAY is a Japan-headquartered diagnostics company with a strong TDM and clinical-chemistry portfolio (e.g., AUTION, A1c testing), making it a regionally concentrated TDM-focused peer comparable to QuantiLight's product category.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/quantilightfsite

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QuantiLight